Skip to main content
. 2009 Jun 9;4:241–250. doi: 10.2147/cia.s3333

Figure 5.

Figure 5

Effect of denusomab vs alendronate head to head trial on bone markers. Reproduced from J Bone Miner Res. 2009;24:153–161,33 with permission of the American Society for Bone and Mineral Research.

Notes: asignificantly different from alendronate, p ≤ 0.0001.